Scarica l'app Stockscreener
51.83
0.02%
-0.01
Dopo l'orario di chiusura:
52.00
0.17
+0.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$51.84
Aprire:
$51.97
Volume 24 ore:
2.07M
Relative Volume:
0.72
Capitalizzazione di mercato:
$9.91B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-21.51
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
-1.41%
1M Prestazione:
+8.54%
6M Prestazione:
+54.53%
1 anno Prestazione:
+68.99%
Intervallo 1D:
$50.49
$52.48
Intervallo di 1 settimana:
$49.75
$52.84
Portata 52W:
$21.72
$52.84
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Confronta BBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
51.83 | 9.56B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
BridgeBio Pharma (BBIO) Receives a Rating Update from a Top Analyst - The Globe and Mail
BridgeBio Pharma Inc. stock momentum explainedInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Applying Elliott Wave Theory to BridgeBio Pharma Inc.July 2025 Action & Pattern Based Trade Signal System - Newser
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - The Manila Times
BridgeBio Pharma (BBIO) Rating Reiterated as 'Buy' by HC Wainwright & Co. | BBIO Stock News - GuruFocus
Phase 3 Trial Update: BridgeBio's Breakthrough ADH1 Drug Encaleret Featured in NIH Expert Webinar - Stock Titan
When is the best time to exit BridgeBio Pharma Inc.Earnings Performance Report & Stepwise Entry and Exit Trade Signals - Newser
What candlestick patterns are forming on BridgeBio Pharma Inc.Market Movement Recap & Expert Approved Momentum Ideas - Newser
Is BridgeBio Pharma Inc. a good ESG investmentProfit Target & Free Weekly Watchlist of Top Performers - khodrobank.com
Chart based analysis of BridgeBio Pharma Inc. trendsPrice Action & Risk Controlled Daily Trade Plans - Newser
Market reaction to BridgeBio Pharma Inc.’s recent newsPortfolio Risk Summary & Real-Time Market Trend Scan - Newser
Backtesting results for BridgeBio Pharma Inc. trading strategies2025 Buyback Activity & Weekly Chart Analysis and Guides - Newser
Strategies to average down on BridgeBio Pharma Inc.2025 Top Decliners & Proven Capital Preservation Methods - Newser
BridgeBio Pharma Inc. recovery potential after sell off2025 Key Highlights & Stepwise Swing Trade Plans - Newser
News impact scoring models applied to BridgeBio Pharma Inc.Trade Exit Summary & Reliable Price Breakout Alerts - Newser
What’s the analyst consensus on BridgeBio Pharma Inc.2025 Top Decliners & Stepwise Swing Trade Plans - khodrobank.com
Can BridgeBio Pharma Inc. withstand a market correctionMarket Sentiment Report & Entry and Exit Point Strategies - khodrobank.com
Using RSI to spot recovery in BridgeBio Pharma Inc.2025 Dividend Review & Long-Term Growth Portfolio Plans - Newser
Short Interest Drops in BridgeBio Pharma Inc. After RallyMarket Performance Report & Weekly High Momentum Picks - beatles.ru
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism - The Manila Times
BridgeBio Pharma Presents Phase 2 Data on Post-Surgical Hypoparathyroidism and Skeletal Dysplasia at ASBMR Annual Meeting 2025 - Quiver Quantitative
New Treatment Hope: BridgeBio's Encaleret Shows Promise in Post-Surgical Hypoparathyroidism Phase 2 Trial - Stock Titan
Is it time to cut losses on BridgeBio Pharma Inc.Trade Volume Report & Long-Term Safe Investment Ideas - Newser
What’s next for BridgeBio Pharma Inc. stock priceLayoff News & Community Verified Watchlist Alerts - Newser
Published on: 2025-09-02 04:42:43 - Newser
Tick level data insight on BridgeBio Pharma Inc. volatilityEarnings Overview Summary & Weekly High Return Opportunities - Newser
Is BridgeBio Pharma Inc. a defensive stock2025 Breakouts & Breakdowns & Verified Short-Term Plans - خودرو بانک
BridgeBio Pharma: Promising Phase 3 Data and Strong Financial Performance Justify Buy Rating - TipRanks
Is BridgeBio Pharma Inc. stock a top performer YTDMarket Performance Summary & Entry Point Strategy Guides - khodrobank.com
Tools to monitor BridgeBio Pharma Inc. recovery probabilityPortfolio Risk Report & Daily Chart Pattern Signal Reports - Newser
How does BridgeBio Pharma Inc. score in quality rankingsJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - khodrobank.com
BridgeBio Pharma Inc. stock volume spike explained2025 Pullback Review & Pattern Based Trade Signal System - Newser
Reversal indicators forming on BridgeBio Pharma Inc. stockQuarterly Trade Summary & Free Verified High Yield Trade Plans - Newser
What to do if you’re stuck in BridgeBio Pharma Inc.July 2025 Outlook & Daily Chart Pattern Signals - Newser
Trendlines Converge — Decision Point for BridgeBio Pharma Inc.2025 Dividend Review & Safe Capital Growth Plans - beatles.ru
BridgeBio says new Attruby data adds to benefit in ATTR-CM - MSN
Using fundamentals and technicals on BridgeBio Pharma Inc.Portfolio Performance Summary & Fast Moving Stock Trade Plans - Newser
Published on: 2025-08-31 13:32:00 - Newser
Analyzing recovery setups for BridgeBio Pharma Inc. investors2025 Fundamental Recap & Daily Stock Momentum Reports - Newser
BridgeBio Pharma Inc. Rebounds From Oversold Zone — Now What getLinesFromResByArray error: size == 0 - newsyoung.net
Here’s What Wall Street Thinks About BridgeBio Pharma (BBIO) - MSN
BridgeBio's Attruby Shows Significant Reduction in Cardiovascular Mortality in ATTR-CM Patients - AInvest
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bridgebio Pharma Inc Azioni (BBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Aug 20 '25 |
Sale |
48.82 |
26,156 |
1,276,927 |
223,090 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):